Bloomberg Originals
@business·5.1M subscribers·49.5K videos
GSK CEO on Drug Pricing, Regulation, Succession
Posted
February 8, 2017
Views
1,690
Likes
9
Engagement
0.53%
February 8, 2017
1,690
9
0.53%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
7:46Now PlayingFeb.08 -- Andrew Witty, chief executive officer at GlaxoSmithKline, discusses drug pricing, how a generic drug from a competitor may impact their outlook for the year ahead, and the main issues for the next CEO taking over on March 31. He speaks on "Bloomberg Daybreak: Americas."
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
